1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anthrax - Pipeline Review, H1 2017

Anthrax - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 142 pages

Anthrax - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax – Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 24 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Anthrax - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anthrax - Overview 7
Anthrax - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Anthrax - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Anthrax - Companies Involved in Therapeutics Development 25
Altimmune Inc 25
Aphios Corp 25
Aradigm Corp 26
AtralCipan 26
ContraFect Corp 27
Crestone Inc 27
Dynavax Technologies Corp 28
Emergent BioSolutions Inc 28
GlaxoSmithKline Plc 29
Green Cross Corp 29
Grifols SA 30
Hawaii Biotech Inc 30
iBio Inc 31
Merck and Co Inc 31
Microbiotix Inc 32
NanoBio Corp 32
Paratek Pharmaceuticals Inc 33
PaxVax Inc 33
Pfenex Inc 34
PharmAthene Inc 34
Planet Biotechnology Inc 35
Protein Potential LLC 35
ProThera Biologics Inc 36
Soligenix Inc 36
Syntiron LLC 37
Tetraphase Pharmaceuticals Inc 37
VLP Biotech Inc 38
Anthrax - Drug Profiles 39
anthrax (virus like particles) vaccine - Drug Profile 39
anthrax + plague vaccine - Drug Profile 40
anthrax vaccine - Drug Profile 41
anthrax vaccine - Drug Profile 43
anthrax vaccine - Drug Profile 44
anthrax vaccine - Drug Profile 45
anthrax vaccine - Drug Profile 46
anthrax vaccine - Drug Profile 47
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 48
ARD-3100 - Drug Profile 49
AV-7909 - Drug Profile 53
BDM-I - Drug Profile 55
CF-306 - Drug Profile 58
CF-307 - Drug Profile 59
CF-308 - Drug Profile 60
ciprofloxacin hydrochloride - Drug Profile 61
CPN-1311 - Drug Profile 62
DPX-Anthrax - Drug Profile 63
DV-230 - Drug Profile 65
Epimerox - Drug Profile 66
EV-035 - Drug Profile 67
GC-1109 - Drug Profile 69
gepotidacin mesylate - Drug Profile 70
GREANX - Drug Profile 73
KKL-35 - Drug Profile 74
Marinus - Drug Profile 75
Monoclonal Antibody for Anthrax - Drug Profile 76
Monoclonal Antibody for Anthrax - Drug Profile 77
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 78
Nasoshield - Drug Profile 79
omadacycline tosylate - Drug Profile 81
PBI-220 - Drug Profile 88
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 90
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 91
Px-563L - Drug Profile 93
Px-563L Second Generation - Drug Profile 95
raxibacumab - Drug Profile 96
RiVax + SGX-204 - Drug Profile 97
rPA-01 - Drug Profile 98
RPA-563 - Drug Profile 99
Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 100
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 101
Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 102
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 103
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 104
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 106
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 107
solithromycin - Drug Profile 108
TP-271 - Drug Profile 121
Anthrax - Dormant Projects 123
Anthrax - Discontinued Products 126
Anthrax - Product Development Milestones 127
Featured News and Press Releases 127
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

List of Tables
Number of Products under Development for Anthrax, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anthrax - Pipeline by Altimmune Inc, H1 2017
Anthrax - Pipeline by Aphios Corp, H1 2017
Anthrax - Pipeline by Aradigm Corp, H1 2017
Anthrax - Pipeline by AtralCipan, H1 2017
Anthrax - Pipeline by ContraFect Corp, H1 2017
Anthrax - Pipeline by Crestone Inc, H1 2017
Anthrax - Pipeline by Dynavax Technologies Corp, H1 2017
Anthrax - Pipeline by Emergent BioSolutions Inc, H1 2017
Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2017
Anthrax - Pipeline by Green Cross Corp, H1 2017
Anthrax - Pipeline by Grifols SA, H1 2017
Anthrax - Pipeline by Hawaii Biotech Inc, H1 2017
Anthrax - Pipeline by iBio Inc, H1 2017
Anthrax - Pipeline by Merck and Co Inc, H1 2017
Anthrax - Pipeline by Microbiotix Inc, H1 2017
Anthrax - Pipeline by NanoBio Corp, H1 2017
Anthrax - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Anthrax - Pipeline by PaxVax Inc, H1 2017
Anthrax - Pipeline by Pfenex Inc, H1 2017
Anthrax - Pipeline by PharmAthene Inc, H1 2017
Anthrax - Pipeline by Planet Biotechnology Inc, H1 2017
Anthrax - Pipeline by Protein Potential LLC, H1 2017
Anthrax - Pipeline by ProThera Biologics Inc, H1 2017
Anthrax - Pipeline by Soligenix Inc, H1 2017
Anthrax - Pipeline by Syntiron LLC, H1 2017
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Anthrax - Pipeline by VLP Biotech Inc, H1 2017
Anthrax - Dormant Projects, H1 2017
Anthrax - Dormant Projects, H1 2017 (Contd..1), H1 2017
Anthrax - Dormant Projects, H1 2017 (Contd..2), H1 2017
Anthrax - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Anthrax, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.